Detransition in Ireland

What is known about detransition among Irish patients and what support exists?

Detransition is not a single clinical outcome. It can mean stopping puberty blockers or cross-sex hormones, reversing a social transition, seeking treatment for unwanted effects, changing one’s legal documents, or coming to identify again with one’s sex. It may be temporary or permanent, voluntary or shaped by external pressure. Crucially, detransition is not synonymous with regret; equally, regret cannot be assumed absent merely because a patient remains in a transition pathway.

Background

Detransition is not a single clinical outcome. It can mean stopping puberty blockers or cross-sex hormones, reversing a social transition, seeking treatment for unwanted effects, changing one’s legal documents, or coming to identify again with one’s sex. It may be temporary or permanent, voluntary or shaped by external pressure. Crucially, detransition is not synonymous with regret; equally, regret cannot be assumed absent merely because a patient remains in a transition pathway.

For Ireland, the central factual problem is that there is no published national register showing how many patients have medically transitioned, stopped treatment, sought reversal or aftercare, or later expressed regret. No public HSE dataset identified for this dossier gives a detransition rate for Irish patients. This means that confident claims that detransition is either rare or common in Ireland go beyond the published Irish record.

The public adult specialist service is the National Gender Service at St Columcille’s Hospital, Loughlinstown, Co Dublin. Its current referral information says it accepts Irish residents who are at least 17 and want to medically transition. A diagnosis of gender dysphoria and prior mental-health assessment are not required simply to make a referral. The service says that, following care, patients may ultimately be discharged back to their GP (National Gender Service, 2026). ([nationalgenderserviceireland.com](https://nationalgenderserviceireland.com/referral-form/))

Children’s provision has been much less settled. The HSE’s review of the implications of the interim Cass report recorded that there was no dedicated Irish CAMHS gender service and that 233 referrals had been made from Ireland to the Tavistock and Portman NHS Foundation Trust through the Treatment Abroad Scheme since 2012 (HSE, 2023). ([hse.ie](https://www.hse.ie/eng/services/publications/clinical-strategy-and-programmes/review-of-the-implications-of-the-cass-report-for-the-provision-of-gender-identity-services-for-children-and-young-people-in-ireland-march-2023-published-version.pdf?utm_source=openai)) This matters because some patients who later question, cease or reverse treatment may have entered care through several jurisdictions and providers, rather than through one Irish pathway.

What the documents say

Irish service documents

The NGS publicly describes itself as a specialist service for people seeking medical and surgical interventions. Its public referral page is directed towards medical transition, not towards people who want to discontinue or reverse it. The site offers general mental-health and community-support signposting, but it does not set out a distinct Irish detransition clinic, published pathway, eligibility criteria, referral form or outcomes audit for detransitioners (National Gender Service, 2026). ([nationalgenderserviceireland.com](https://nationalgenderserviceireland.com/referral-form/))

This absence should not be overstated as proof that no individual help is available. A GP can address immediate physical and mental-health needs, arrange relevant blood tests or specialist referral, and make an urgent referral where clinically indicated. Someone who has had surgery abroad may also need ordinary surgical, endocrine, fertility, sexual-health or psychological care in Ireland. But general access to healthcare is not the same thing as a named, multidisciplinary detransition service with recognised expertise in hormonal withdrawal, fertility implications, surgical complications and trauma-informed counselling.

In April 2024, Dr Paul Moran, a consultant psychiatrist associated with the NGS, told The Irish Times that a “growing number” of people had contacted the service seeking to detransition and that he proposed a specific support programme (The Irish Times, 2024). That is an important statement from an Irish clinician, but it is not a figure, denominator, peer-reviewed study or published service specification. It therefore cannot establish an Irish prevalence rate. ([irishtimes.com](https://www.irishtimes.com/health/2024/04/29/what-now-for-transgender-healthcare-in-ireland-after-publication-of-the-cass-review/?utm_source=openai))

HSE policy development

The HSE is developing a new Model of Care for Gender Healthcare under National Clinical Lead Dr Karl Neff. The HSE says the work has two foundations: an evidence-base review and an experience-base review involving service users, families, clinicians and other stakeholders. Its page states that initial searching and screening for the review question, “What are the clinical outcomes of medical transition?”, was completed in March 2026; analysis is continuing and results will be published when available (HSE, 2026). ([healthservice.hse.ie](https://healthservice.hse.ie/staff/information-healthcare-workers/gender-healthcare/))

This is relevant to detransition because robust follow-up data are needed to distinguish continuation, discontinuation, re-transition, regret, adverse effects and unmet aftercare. As of September 2026, the HSE page does not publish the completed review’s findings or an Irish data-collection plan specifically for detransition outcomes.

International standards and the Cass Review

The Cass Review, commissioned by NHS England and published on 10 April 2024, stated that provision should exist for people considering detransition, including people who may not wish to return to the clinicians or services involved in their earlier care (Cass Review, 2024). NHS England subsequently described the absence of a consistent clinical approach for adults seeking detransition and called for evidence to inform a pathway (NHS England, 2025). ([england.nhs.uk](https://www.england.nhs.uk/long-read/review-of-nhs-adult-gender-dysphoria-clinics/?utm_source=openai))

WPATH’s Standards of Care Version 8 takes a different overall approach to gender healthcare but also recognises detransition as a legitimate clinical need. It recommends a comprehensive multidisciplinary assessment for adults seeking gender-related hormonal or surgical intervention in the context of detransition (WPATH, 2022). In short, the major documents differ on wider questions of evidence and access, but neither supports abandoning people who wish to stop or reconsider transition.

The positions

Trans-rights organisations and many patients argue that Irish gender healthcare is excessively centralised, under-resourced and inaccessible. From this perspective, lengthy waiting times and restrictive assessment processes can drive people towards private, overseas or self-managed hormones. They caution that public discussion of detransition can be used to justify withholding appropriate care from trans people, including those for whom medical transition is beneficial.

Clinicians and gender-critical campaigners argue that the lack of long-term outcome data requires greater caution, especially where young people present with autism, mental-health difficulties, trauma, same-sex attraction or other complex needs. They maintain that careful assessment is not hostility to patients, and that a service which cannot identify or support those who later regret treatment has failed an essential duty of care.

A fair account recognises two separate obligations: people distressed by gender incongruence deserve respectful, timely and competent healthcare; people who pause, stop or regret a transition deserve equally respectful, timely and competent healthcare. Neither group should be erased to advance the other’s case.

Interpretation

Beyond Gender’s reading is that Ireland has a serious evidence and accountability gap. The available Irish record confirms that clinicians are encountering people seeking detransition, but public authorities have not published even the basic information needed to understand the scale, timing, reasons, treatments involved or support required. “Growing number” is not an adequate substitute for systematic data.

The present NGS referral rule is also revealing. It is explicitly designed for people who want medical transition. A person who regrets treatment, has stopped hormones, or needs help living comfortably in their sex may reasonably feel that the service was not designed for them. The Cass Review’s warning that some people may not want to re-engage with the service previously involved in their care is directly relevant in Ireland.

This is not an argument for treating every trans-identifying person as a future detransitioner. It is an argument for informed consent that is genuinely informed: sex-specific effects, fertility, sexual function, bone health, mental health, uncertainty in the evidence, the possibility of changed identity, and a realistic route to aftercare must all be discussed before treatment. A healthcare system should be capable of supporting people whatever conclusion they reach.

Open questions

The Oireachtas should seek clear answers to basic questions: How many NGS patients have reported stopping hormones, seeking reversal, or expressing regret? How many Irish patients received hormones or surgery privately or abroad? What follow-up is undertaken after discharge? How are serious adverse events, fertility outcomes and surgical complications recorded? Parliamentary questions in 2024 specifically sought clarification on how often NGS patients detransitioned and how many expressed regret, demonstrating that these questions have entered the Irish political record (Dáil Éireann, 2024). ([data.oireachtas.ie](https://data.oireachtas.ie/ie/oireachtas/parliamentaryBusiness/questionsPaper/dail/2024/2024-07-02_dail-question-paper-tues_en.pdf?utm_source=openai))

The HSE’s forthcoming Model of Care should publish a clear pathway for people considering detransition, separate where necessary from transition services, with GP guidance, endocrinology, mental-health support, fertility counselling, surgical aftercare and transparent outcome reporting. It should also distinguish carefully between discontinuation due to external pressures and discontinuation because a person’s understanding of themselves has changed. Without that distinction, neither patients nor policymakers can properly interpret the data.

Finally, legal recognition should not be confused with medical necessity. The Gender Recognition Act 2015 provides a route to State recognition of a person’s preferred gender; for adults it does not require medical transition. For 16- and 17-year-olds, the Act provides for a court process with additional safeguards (Gender Recognition Act 2015). ([irishstatutebook.ie](https://www.irishstatutebook.ie/eli/2015/act/25/section/12/enacted/en/html?utm_source=openai)) The separation matters: a legal status cannot answer a clinical question, and no legal framework removes the health service’s responsibility to collect outcomes and care for those who change course.

On the Irish timeline

Episodes on this subject

From Gay Man to Transwoman... and Back Again | Michael Kerr